Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Change in Inventory (2022 - 2025)

Historic Change in Inventory for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $6.0 million.

  • Indivior Pharmaceuticals' Change in Inventory changed 0.0% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.0 million, marking a year-over-year decrease of 11917.81%. This contributed to the annual value of $43.0 million for FY2024, which is 61666.67% up from last year.
  • Indivior Pharmaceuticals' Change in Inventory amounted to $6.0 million in Q3 2025, which was down 0.0% from -$17.0 million recorded in Q2 2025.
  • Over the past 5 years, Indivior Pharmaceuticals' Change in Inventory peaked at $52.0 million during Q4 2022, and registered a low of -$17.0 million during Q2 2025.
  • Over the past 4 years, Indivior Pharmaceuticals' median Change in Inventory value was $2.0 million (recorded in 2024), while the average stood at $5.6 million.
  • Per our database at Business Quant, Indivior Pharmaceuticals' Change in Inventory skyrocketed by 64000.0% in 2024 and then plummeted by 31250.0% in 2025.
  • Over the past 4 years, Indivior Pharmaceuticals' Change in Inventory (Quarter) stood at $52.0 million in 2022, then plummeted by 38.46% to $32.0 million in 2023, then tumbled by 93.75% to $2.0 million in 2024, then soared by 200.0% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q3 2025, -$17.0 million for Q2 2025, and -$5.0 million during Q1 2025.